more from seeking alpha
Takeover Targets
New: Today, 12:46 AM
Comments (23)
|
+ Follow
« Prev | Next »
10/04 Wall Street Rumors: Our Japan source says, Daiichi Sanko legal department is ready to negotiate with Esperion Therapeutics (ESPR) before the October 16th discovery date, on 10/03 more legal documents show at this time Daiichi has failed to present necessary documents to the court. We had the Case document 1:23-cv-02568 reviewed. It is obvious Daiichi Sankyo Europe $300 million milestone payment agreement was deliberately denied to use a tactic to negotiate a better offer, and more than likely an acquisition offer. Esperion has further milestone agreements between Daiichi and Otsuka totaling $1.5 billion. After careful review, Esperion is completely due the full $300 million milestone payment. Pointed out in the legal document noting the New England Journal of Medicine which reported 23% cardiovascular risk reduction, and entitles Esperion to the full $300 million payment based on the 20% marker agreement, further more Daiichi Sankyo Europe released news on 8/26:
New secondary analysis of CLEAR Outcomes data for bempedoic acid show significant risk reduction of total cardiovascular events and no increase of new-onset diabetes in patients at high-risk of cardiovascular disease
- Results from a prespecified, secondary analysis of total cardiovascular (CV) events during the CLEAR Outcomes trial demonstrate that bempedoic acid, marketed as NILEMDO®? in Europe, provides a 20% reduction in the risk of total number of serious CV events in high-risk patients, complementing the previously reported 13%* reduction for the primary analysis.1,2
- A separate sub-analysis of the CLEAR Outcomes trial data shows patients with diabetes derive greater absolute benefit from bempedoic acid; furthermore, treatment does not increase HbA1c levels or the incidence of new-onset diabetes.3
- These findings support the benefits of long-term treatment with bempedoic acid to not only lower LDL-C but also reduce the risk for any – first and subsequent – CV events.
More details to come.
